Collecting urine and tumor samples to test a genetic test for bladder cancer
Gathers urine and tumor samples from adults being checked or treated for urothelial cancer.
Key facts
- Who runs it
- Convergent Genomics, Inc.
- Where
- Austin, Chicago, Cincinnati, Dallas, Grayslake, Hanover, Las Vegas, Mount Prospect, Nashville, New York, Niles, Oceanside, Royal Oak, San Antonio, San Diego, San Jose, Virginia Beach, and Wheaton, United StatesSee the 21 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
- Status
- Recruiting
- People taking part
- 2,500 people, planned
- Started
- 15 Oct 2019
- Expected to end
- Dec 2034
- Type of study
- Observational, 2 groups
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bladder or upper urinary tract cancer, or past urothelial cancer. It also takes adults with blood in the urine and no such cancer history.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Cancer group: bladder cancer (muscle invasive or non-muscle invasive) or upper urinary tract cancer, or past urothelial cancer with no sign of it now. Control group: blood in the urine (visible or only seen in tests).
- Earlier treatment
- Cancer group: scheduled for surgery to remove a bladder tumor (TURBT) or a urinary tract biopsy, or for chemotherapy before surgery (NAC) and/or removal of the bladder (radical cystectomy). Other bladder cancer studies are allowed.
Main reasons for not taking part
- Cancer group: symptomatic urinary tract infection at the time of the first urine collection
- Cannot give at least 20cc of urine
- Control group: current or past bladder, upper tract, kidney or prostate cancer
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- GROUP 1: Bladder Cancer and/or Upper Tract UCC
- Male or female ≥ 18 years of age who are scheduled for transurethral resection of bladder tumor (TURBT) and/or biopsy of urinary tract or
- Patients on surveillance who are negative for recurrence or tumor at the time of study enrollment but have had previous urothelial cell carcinoma (UCC) or
- Patients with muscle invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC) scheduled for NAC and/or subsequent radical cystectomy (RC)
- Able to provide consent prior to diagnostic TURBT, nephroureterectomy, or administration of NAC and/or RC
- Able to provide at least 20cc urine. If patient cannot void sufficient volume of urine, urologist can pull urine from the bladder via catheter or cystoscope. Urine should not be collected immediately after resection
- Participation in other bladder cancer studies is allowed. Experimental therapy must be documented in the case report forms; GROUP 2: Hematuria Controls
- Male or female ≥ 18 years of age presenting with gross or microscopic hematuria as defined by standard of care
- No evidence of and/or history of bladder cancer, upper tract UCC, kidney cancer and/or prostate cancer at the time of collection
- Able to provide consent
- Able to provide at least 20cc urine
- Participation in other studies is allowed. Experimental therapy must be documented in the case report forms
Who cannot take part
- GROUP 1: Bladder Cancer and/or Upper Tract UCC
- Clinical, symptomatic urinary tract infection at time of initial urine collection
- Evidence and/or History of bladder cancer, upper tract UCC, kidney cancer and/or prostate cancer at the time of collection
- Unable to provide adequate urine sample; GROUP 2: Hematuria Controls
Where in United States
Also in 1 other country, 2 sites
- Midtown Urology AssociatesAustin, United StatesNo longer taking part
- Urology Austin - Medical Park TowerAustin, United StatesNo longer taking part
- Urology Austin - Round RockAustin, United StatesNo longer taking part
- UroPartners,LLCChicago, United StatesNo longer taking part
- The Urology GroupCincinnati, United StatesNo longer taking part
- UT Southwestern Medical CenterDallas, United StatesContact: Perla LopezTaking people
- UroPartners, LLCGrayslake, United StatesNo longer taking part
- Chesapeake Urology Research AssociatesHanover, United StatesNo longer taking part
- Sheldon J. Freedman MD LTDLas Vegas, United StatesNo longer taking part
- UroPartners, LLCMount Prospect, United StatesNo longer taking part
- Urology Associates, P.C.Nashville, United StatesNo longer taking part
- Manhattan Medical Research PracticeNew York, United StatesNo longer taking part
- UroPartners, LLCNiles, United StatesNo longer taking part
- Urology San DiegoOceanside, United StatesNo longer taking part
- Comprehensive UrologyRoyal Oak, United StatesNo longer taking part
- Urology San AntonioSan Antonio, United StatesNo longer taking part
- UT Health San AntonioSan Antonio, United StatesNo longer taking part
- Genesis Research, LLCSan Diego, United StatesNo longer taking part
- Urology Associates of Silicon ValleySan Jose, United StatesNo longer taking part
- Urology of VirginiaVirginia Beach, United StatesNo longer taking part
- UroPartners, LLCWheaton, United StatesNo longer taking part
About the trial
What the trial wants to find out
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
The 2 groups in the trial
- Bladder Cancer and/or Upper Tract Urothelial Cell Carcinoma (UCC)
- Hematuria Controls
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
- Plain-language title
- Collecting urine and tumor samples to test a genetic test for bladder cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 June 2026